No Data
Invivyd at the Ready for Upcoming Respiratory Virus Season With PEMGARDA (Pemivibart) to Help Protect Vulnerable Immunocompromised Persons From COVID-19
Buy Rating Affirmed for Invivyd: Strong Product Performance and Strategic Market Initiatives
Invivyd to Participate in Upcoming Investor Conferences
Express News | Invivyd Inc - Preliminary Data Readouts Expected in Q4 2024
Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA
Express News | Invivyd Doses First Participants in Phase 1 Clinical Trial of Vyd2311, a Next Generation Monoclonal Antibody Candidate for Covid-19, Building on the Success of Pemgarda™